Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Net Income towards Common Stockholders: 2012-2024

Historic Net Income towards Common Stockholders for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$409.2 million.

  • Ascendis Pharma A's Net Income towards Common Stockholders fell 32.86% to $73.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.2 million, marking a year-over-year decrease of 35.32%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • As of FY2024, Ascendis Pharma A's Net Income towards Common Stockholders stood at -$409.2 million, which was up 21.00% from -$518.0 million recorded in FY2023.
  • Over the past 5 years, Ascendis Pharma A's Net Income towards Common Stockholders peaked at -$409.2 million during FY2024, and registered a low of -$595.0 million during FY2022.
  • Over the past 3 years, Ascendis Pharma A's median Net Income towards Common Stockholders value was -$518.0 million (recorded in 2023), while the average stood at -$507.4 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Net Income towards Common Stockholders crashed by 219,311.36% in 2020, and later climbed by 21.00% in 2024.
  • Yearly analysis of 5 years shows Ascendis Pharma A's Net Income towards Common Stockholders stood at -$478.4 million in 2020, then climbed by 8.27% to -$438.8 million in 2021, then crashed by 35.60% to -$595.0 million in 2022, then climbed by 12.94% to -$518.0 million in 2023, then climbed by 21.00% to -$409.2 million in 2024.